Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, July 2, 2019
[ Tue, Jul 02nd 2019
] - WOPRAI
[ Tue, Jul 02nd 2019
] - WOPRAI
[ Tue, Jul 02nd 2019
] - WOPRAI
[ Tue, Jul 02nd 2019
] - WOPRAI
[ Tue, Jul 02nd 2019
] - WOPRAI
[ Tue, Jul 02nd 2019
] - WOPRAI
Mon, July 1, 2019
[ Mon, Jul 01st 2019
] - WOPRAI
[ Mon, Jul 01st 2019
] - WOPRAI
[ Mon, Jul 01st 2019
] - WOPRAI
[ Mon, Jul 01st 2019
] - WOPRAI
[ Mon, Jul 01st 2019
] - WOPRAI
[ Mon, Jul 01st 2019
] - WOPRAI
[ Mon, Jul 01st 2019
] - WOPRAI
[ Mon, Jul 01st 2019
] - WOPRAI
[ Mon, Jul 01st 2019
] - WOPRAI
[ Mon, Jul 01st 2019
] - WOPRAI
[ Mon, Jul 01st 2019
] - WOPRAI
[ Mon, Jul 01st 2019
] - WOPRAI
[ Mon, Jul 01st 2019
] - WOPRAI
[ Mon, Jul 01st 2019
] - WOPRAI
Brian Abrahams Maintained (SRPT) at Buy with Increased Target to $220 on, Jul 1st, 2019
Brian Abrahams of RBC Capital, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $188 to $220 on, Jul 1st, 2019.
Brian has made no other calls on SRPT in the last 4 months.
There are 2 other peers that have a rating on SRPT. Out of the 2 peers that are also analyzing SRPT, 0 agree with Brian's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Brian
- Joel Beatty of "Citigroup" Maintained at Strong Buy with Decreased Target to $190 on, Thursday, May 16th, 2019
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $165 on, Tuesday, May 14th, 2019
Similar Stocks and Investing Articles
[ Thu, May 16th 2019
] - WOPRAI
[ Tue, May 14th 2019
] - WOPRAI
[ Thu, May 09th 2019
] - WOPRAI
[ Tue, Nov 06th 2018
] - WOPRAI
[ Mon, Jul 16th 2018
] - WOPRAI
[ Thu, Jul 12th 2018
] - WOPRAI
[ Thu, Jun 21st 2018
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Mon, Apr 22nd 2013
] - WOPRAI
[ Tue, Apr 09th 2013
] - WOPRAI